Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Complex market dynamics of the Irritable Bowel Syndrome (IBS) treatment sector across the Americas can be better understood when one considers several issues that influence its growth and development. The disease IBS is spreading between North and South America at a higher rate than before because it has become common knowledge in society that this condition exists. Consequently, pharmaceutical companies are investing in developing new solutions to meet these needs. This has led to an expansion of the drug pipeline from new compounds to repurposed drugs fighting for approval by regulators and penetration of the market.
The Americas IBS treatment market is also influenced by lifestyle changes, dietary habits and stress factors that accompany it. Many things cause the high prevalence of this disease such as change in lifestyle, food patterns and stress levels among others. As a result, pharmaceutical companies are engaged in research and development activities to introduce novel therapies and medications. To this end, they compete with each other in terms of how well they can relieve symptoms but most importantly treat its real underlying causes. Thereby resulting into a rich pipeline of drugs awaiting regulatory approvals in addition to those going through clinical trials.
Another factor contributing to shaping the aforementioned market dynamics is regulation. In order to ensure safety and effectiveness of treatments for IBS stringent regulations have been put in place by health authorities operating within America’s jurisdiction. Including clinical trial requirements, post marketing surveillance as well as approval procedures which makes it necessary for products being marketed on such settings undergo more scrutiny compared what happens when they were still under development stage. Companies therefore have to prove that their products work efficiently or are safe for use thus paying more attention on patient interests; hence establishing relationships with healthcare providers which make them trustworthy enough.
Again awareness about patients significantly affects this dynamic setting’s operation structure too.A s information continues becoming easily available people are increasingly becoming proactive by searching for ways on how best they could be treated if infected with any diseases.Therefore patient centered approaches have becomes more prominent due to the increased number of educational activities, support programs and other online resources that help sufferers of IBS at different stages. After learning what their condition means these patients will always want to be in control, an aspect that has affected the market trends as well as adoption of specific therapies.
In addition, strategic alliances with healthcare providers and research institutions are essential ingredients for boosting growth in this market. These linkages enable innovativeness among people and enhance transferability of knowledge that is essential for any form of commercialization process in relation to IBS treatments. By combining the pharmaceuticals along with behavioral psychotherapies or lifestyle changes, more inclusive ways are possible that would address the multiple aspects of IBS.
However, challenges persist within the Americas IBS treatment market. Widespread uptake may still be hindered by economic concerns especially because there still exists a significant variation in healthcare infrastructure across countries. Furthermore, price wars have become common which force such businesses to ensure they make profits but also offer fair rates for their products.”
IBS Treatment Market Highlights:
Americas Irritable Bowel Syndrome (IBS) Treatment Market Scenario
America's Irritable bowel syndrome (IBS) treatment market is projected to reach USD 3952.8 Million by 2030 at 13.8% CAGR during the forecast period 2022-2030.Irritable bowel syndrome (IBS) is a common disorder that affects the digestive system. IBS is characterized by symptoms such as stomach cramps, bloating, diarrhea, and constipation, which impacts one’s everyday life. Although the cause of IBS is unknown, but few factors that cause IBS are severe infection, inflammation in the intestines, muscle contractions in the intestine, changes in bacteria in the gut, and abnormalities in the nerves. Rising prevalence of gastrointestinal diseases and disorder, geriatric population, unhealthy diet, anxiety, depression, and changing lifestyle in Americas are the key drivers of the Americas Irritable bowel syndrome (IBS) treatment market. Moreover, strong clinical pipeline and government support is fuelling the market in this region. According to an updated report by the Anxiety and Depression Association of America, in 2017, the most common mental disorder was anxiety in the United States, affecting approximately 40 million adults over 18 years every year. Additionally, According to a report of the National Institute of Mental Health, in 2015, approximately 16.1 adults over 18 years in the United States had at least one major depressive episode in the past one year, which is 6.7% of all the U.S. adults. These number generate the huge demand for better treatment in this region.
Hence, most of the companies are more into mergers, acquisitions, and collaboration activities in order to provide better treatment procedures. In this regard, Allergan Plc. in January 2017, entered into a licensing agreement with Assembly Biosciences, Inc. for worldwide rights to Assembly's microbiome GI development programs. Also, in October 2016, Allergan Plc. announced the formation of the IBS CounSEL, group of experts dedicated to improve diagnosis and management of irritable bowel syndrome (IBS) by providing support. These merger and acquisition help the companies to introduce quality treatment and expand the product line within the region. Companies are also focusing on research and development activities to get better approach to treat IBS. In this regard, in September 2017, Sucampo Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has accepted the application of supplemental new drug application (sNDA) for lubiprostone (AMITIZA) in children.
Furthermore, increasing consumer awareness about irritable bowel syndrome increase the footfall of patient in clinics and hospitals. Furthermore, increasing spending in the healthcare domain fuelling the growth of the IBS treatment market. According to the Centers for Medicare & Medicaid Services, in 2015, the U.S. healthcare spending increased by 5.8% reaching USD 3.2 trillion. In 2016, healthcare spending in North America had increased to some extent.
However, strict FDA regulations and unsatisfactory effectiveness of the treatment may hinder the growth of America's Americas Irritable bowel syndrome (IBS) treatment market during the forecast period.
Research Methodology
 
Source: IBS - American Gastroenterological Association, Irritable Bowel Syndrome Association, U S Food and Drug Administration, World Health Organization, Directorate of Industries, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation
Americas Irritable Bowel Syndrome (Ibs) Treatment Market SegmentationÂ
The Americas Irritable bowel syndrome (IBS) treatmen market is segmented on the basis of types, drugs type, and end user.
On the basis the types, irritable bowel syndrome (IBS) treatment market is segmented into IBS-D, IBS-C, IBS-M.
On the basis of the drugs type, irritable bowel syndrome (IBS) treatment market is segmented into lubiprostone, linaclotide, eluxadoline, rifaximin, alosetron, and others.
On the basis of the end users, irritable bowel syndrome (IBS) treatment market is segmented into hospitals, clinics, and research laboratories.
Figure: Americas Irritable bowel syndrome (IBS) treatment market, by type, 2016 (%)
Source: IBS - American Gastroenterological Association, Irritable Bowel Syndrome Association, U S Food and Drug Administration, World Health Organization, Directorate of Industries, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation
irritable bowel syndrome (IBS) treatment market Key Findings
- The Americas Irritable bowel syndrome (IBS) treatmen market is estimated at USD 1,959.5 million in 2016.
- IBS-C is the fastest growing segment, which is projected grow at a CAGR of 9.6% during the forecast period 2017-2023.
- Linaclotide is the fastest growing drugs type segment, which is expected to USD 1,164.8 million by 2023.
- The United States captured the largest market of Americas and is expected to USD 2,660.9 million by 2023.
Americas Irritable Bowel Syndrome (Ibs) Treatment Market Regional Analysis
The Americas region is divided into North America and South America. North America command the largest market of IBS treatment owing to the well presence of health care structure, government support, various research and development programs, increasing sensitivity and specificity for diagnosing IBS, aware and concerned individual, and presence of well-developed clinical laboratories. Moreover, the presence of strong economic conditions, and the focus of research institutions on updating technology for new and advanced IBS treatment fuel the growth of the market in this region. Also, the countries in this region have multiple companies that are involved in the IBS treatment business. North America is further divided into the U.S. and Canada. Both of these countries have good economic growth and a great standard of living. According to a report published by the International Foundation for Functional Gastrointestinal Disorders, in 2016, functional gastrointestinal (GI) and motility disorders are the most common GI disorders which accounted for 1 in 4 people or more in the United States.
Irritable Bowel Syndrome (Ibs) Treatment Market Key Players
Some of the key players in this Americas Irritable bowel syndrome (IBS) treatment market are Allergan Plc (Ireland), Sucampo Pharmaceuticals (U.S.), Ironwood Pharmaceuticals, Inc. (U.S.), Astellas Pharma Inc. (Japan), Valeant Pharmaceuticals (Canada), Abbott Laboratories (U.S.), Synergy Pharmaceuticals, Inc. (U.S.), Ardelyx, Inc. (U.S.), Nestle (Switzerland), Sebela Pharmaceuticals (Ireland), Probi (Sweden), Alfasigma USA, Inc. (Italy), RedHill Biopharma Ltd. (Israel), AstraZeneca (U.K), Ipsen (France), Novartis AG (Switzerland), Takeda Pharmaceutical Company Ltd (Japan), Synthetic Biologics, Inc. (U.S.), Protagonist Therapeutics Inc. (U.S.), Pfizer Inc (U.S.), Lexicon Pharmaceuticals, Inc. (U.S.), Innovate Biopharmaceuticals (U.S.), 4D pharma plc (U.K).
Intended Audience
- Pharmaceutical Companies
- Medical Devices Companies
- Research and Development (R&D) Companies
- Market Research and Consulting Service Providers
- Potential Investors
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
